| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| Other Sizes |
Ibandronate sodium monohydrate (BM210955; RPR102289A) is a bisphosphonate medication used to treat osteoporosis. It works by boosting bone mineral density, stopping resorption, and reducing osteoclast activity.
| ln Vitro |
Ibandronate (1.25–2 μM) significantly slows the growth of endothelial cells, while ibandronate (2 μM) also slows the formation of capillary-like tubes and speeds up endothelial cell apoptosis. Ibandronate (< 100 μM) increases VEGF expression in endothelial cells in a dose-dependent manner. [1] In a dose-dependent manner, ibandronate (< 100 μM) inhibits the growth of the two prostate cancer cell lines, LNCaP and PC-3. [2]
|
|---|---|
| ln Vivo |
Ibandronate significantly lowers the risk of new morphometric vertebral fractures in osteoporotic women after 3 years of treatment when given either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). After three years of treatment, ibandronate significantly and gradually raises the BMD of the lumbar spine in osteoporotic women by 6.5% and 5.7%, respectively, when taken either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every three months).[3] Ibandronate ( 125 mg/kg s.c.) increases bone mineral density (BMD), trabecular bone volume and number, load to failure (Fmax), and yield load in long bones and vertebrae in ovariectomized rats.Additionally, all doses completely prevent increased trabecular separation in ovariectomized rats. [4]
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Ibandronate sodium has a low oral absorption rate (average absorption rate of 6% in adults on an empty stomach, and almost no absorption when taken with food), therefore breastfed infants are unlikely to absorb ibandronate sodium. However, since there is currently no information on the use of ibandronate sodium during lactation, other medications may be preferred, especially for breastfed newborns or premature infants. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. |
| References | |
| Additional Infomation |
Ibandronate sodium is the sodium salt form of ibandronate, a synthetic nitrogenous bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, leading to a reduction in geraniol-geraniol GTPase signaling protein and inducing osteoclast apoptosis. This drug increases bone mineral density, reduces bone remodeling, inhibits osteoclast-mediated bone resorption, and alleviates metastasis-related and corticosteroid-related bone pain. Aminobisphosphonates are potent bone resorption inhibitors. They are used to treat hypercalcemia associated with malignancies, prevent fractures and skeletal complications in patients with breast cancer bone metastases, and treat and prevent postmenopausal osteoporosis. See also: Ibandronate sodium (note moved to). Indications: Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see Section 5.1). It has been shown to reduce the risk of vertebral fractures, but its efficacy in femoral neck fractures has not been established.
Bandronate sodium is indicated for: prevention of skeletal events (pathological fractures, skeletal complications requiring radiation therapy or surgery) in patients with breast cancer bone metastases; and treatment of hypercalcemia caused by tumors with or without metastases. Treatment of hypercalcemia caused by tumors with or without metastases. |
| Molecular Formula |
C9H24NNAO8P2
|
|---|---|
| Molecular Weight |
359.22
|
| Exact Mass |
359.087
|
| Elemental Analysis |
C, 30.09; H, 6.73; N, 3.90; Na, 6.40; O, 35.63; P, 17.24
|
| CAS # |
138926-19-9
|
| Related CAS # |
Ibandronic acid;114084-78-5;Ibandronate Sodium;138844-81-2
|
| PubChem CID |
23663991
|
| Appearance |
Solid powder
|
| Boiling Point |
587.8ºC at 760 mmHg
|
| Melting Point |
84ºC (dec)
|
| Flash Point |
309.3ºC
|
| Vapour Pressure |
2.88E-16mmHg at 25°C
|
| LogP |
0.873
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
21
|
| Complexity |
377
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(P(O)(O)=O)(P(O)([O-])=O)CCN(C)CCCCC.[Na+].O
|
| InChi Key |
VBDRTGFACFYFCT-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1
|
| Chemical Name |
sodium;hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate;hydrate
|
| Synonyms |
Ibandronate sodium monohydrate; Boniva; Ibandronate sodium; Sodium trihydrogen (1-hydroxy-3-(methylpentylamino)propylidene)diphosphonate, monohydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~25 mg/mL (~69.6 mM)
DMSO: <1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (69.59 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7838 mL | 13.9190 mL | 27.8381 mL | |
| 5 mM | 0.5568 mL | 2.7838 mL | 5.5676 mL | |
| 10 mM | 0.2784 mL | 1.3919 mL | 2.7838 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
